Delek Group’s PHAXIAM Therapeutics S.A.. American Depositary Shares PHXM Stock Holding History

Delek Group’s Portfolio PHXM Stock Details PHXM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$489K	Hold	7,000	–	–	0.02%	185
2019 Q1	$528K	Hold	7,000	–	–	0.02%	175
2018 Q4	$487K	Hold	7,000	–	–	0.02%	185
2018 Q3	$596K	Hold	7,000	–	–	0.03%	202
2018 Q2	$782K	Hold	7,000	–	–	0.03%	203
2018 Q1	$1.47M	Hold	7,000	–	–	0.08%	168
2017 Q4	$1.54M	Buy	+7,000	New	+$1.65M	0.08%	168

Other funds holding PHXM

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Delek Group's PHXM Position: Q2 2019 in Review

Delek Group held its PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) position steady in Q2 2019 at 7,000 shares worth $489K. The position accounts for 0.02% of the portfolio, ranked #185.

Delek Group first reported a position in PHXM in Q4 2017 and has held it in 7 quarters since. The position peaked at $1.54M in Q4 2017. 5 funds tracked by Wall St. Rank hold PHXM as of Q2 2019.

Delek Group held 7,000 shares of PHAXIAM Therapeutics S.A.. American Depositary Shares worth $489K as of Q2 2019.
Delek Group left its PHAXIAM Therapeutics S.A.. American Depositary Shares share count unchanged in Q2 2019.
PHAXIAM Therapeutics S.A.. American Depositary Shares made up 0.02% of Delek Group's portfolio in Q2 2019, its #185 holding.
Delek Group first reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares in Q4 2017 and has held it in 7 quarters since.
Delek Group's PHAXIAM Therapeutics S.A.. American Depositary Shares position peaked at $1.54M in Q4 2017.
5 funds tracked by Wall St. Rank held PHAXIAM Therapeutics S.A.. American Depositary Shares as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.